Workflow
枸橼酸西地那非口崩片
icon
Search documents
九洲药业: 浙江九洲药业股份有限公司关于控股子公司获得药品注册证书的公告
Zheng Quan Zhi Xing· 2025-07-01 16:07
Group 1 - The company Zhejiang Jiuzhou Pharmaceutical Co., Ltd. announced that its subsidiary Zhejiang Jiuzhou Biopharmaceutical Co., Ltd. received a drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration [1][2] - The drug is classified as a chemical drug of category 4, with a specification of 50mg and a registration number valid until June 23, 2030 [1] - The total sales of Sildenafil Citrate tablets in the domestic medical and retail market reached 5.217 billion RMB in 2023 [2] Group 2 - The approval of the drug registration certificate enhances the company's product pipeline and market competitiveness [2] - The company has invested approximately 13.52 million RMB in the research and development of Sildenafil Citrate Orally Disintegrating Tablets [2]
九洲药业:控股子公司获得枸橼酸西地那非口崩片药品注册证书
news flash· 2025-07-01 07:46
Core Viewpoint - The company, Jiuzhou Pharmaceutical, announced that its subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd., has received the drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration of China [1] Group 1: Company Developments - The drug is an iterative formulation of Sildenafil developed by Pfizer, which was approved for import in China in 2019 [1] - Jiuzhou Pharmaceutical has invested approximately 13.52 million RMB in the research and development of Sildenafil Citrate Orally Disintegrating Tablets [1] - The acquisition of the drug registration certificate enhances the company's product pipeline and market competitiveness, although it is not expected to have a significant impact on the company's performance in the short term [1] Group 2: Market Context - The total sales revenue (end-user price) of Sildenafil Citrate tablets in the domestic medical and retail market reached 5.217 billion RMB in 2023 [1] - Major competitors in the market that have also received the drug registration certificate include Sichuan Kelun Pharmaceutical Co., Ltd. and Guangdong Tianenkang Pharmaceutical Co., Ltd. [1]
今年来第四家!昔日明星药企,今成A股黄花!
IPO日报· 2025-05-29 14:38
Core Viewpoint - *ST Longjin (002750.SZ) has been announced for delisting by the Shenzhen Stock Exchange due to continuous financial losses and failure to meet revenue thresholds [1][7]. Company Overview - *ST Longjin, officially known as Kunming Longjin Pharmaceutical Co., Ltd., was established in September 1996 and listed on the Shenzhen Stock Exchange in 2015. The company focuses on the development, research, production, and sales of therapeutic drugs for cardiovascular and metabolic diseases, with its main product being the Longjin injection of Ligusticum chuanxiong [5]. - The company experienced stable revenue growth in its first three years post-listing, with revenues of 181 million, 224 million, and 304 million yuan, and net profits of 54 million, 58 million, and 19 million yuan respectively from 2015 to 2017. However, since 2018, the company's profitability has sharply declined, with net profits remaining negative from 2019 onwards [5][7]. Financial Performance - In 2024, *ST Longjin reported annual revenue of 66 million yuan, a year-on-year decline of 23.25%, marking five consecutive years of revenue below 100 million yuan. The net loss was 41 million yuan, although this represented a 41.58% improvement year-on-year. However, the company still reported a non-recurring net loss of 50 million yuan [7]. - The company's reliance on a single product, the Longjin injection, has been detrimental, as this product has consistently accounted for over 90% of its revenue. Following regulatory changes and price reductions, the sales volume of this product dropped significantly, leading to a devastating impact on the company's financial health [8][9]. Market Challenges - The Longjin injection's sales fell by nearly 20% in 2017 due to regulatory warnings about severe allergic reactions. In 2021, the product's price was drastically reduced by 67% during a procurement process, leading to a further decline in sales [8]. - The company has attempted to diversify its product offerings and explore new markets, including industrial hemp, but these efforts have largely failed. The industrial hemp initiative faced regulatory challenges and a reduction in planting area, while the development of cardiovascular generic drugs has been slow, with the first product only receiving approval at the end of 2024 [10][11]. Industry Context - Since 2025, three other traditional Chinese medicine injection companies have also faced delisting from the A-share market due to similar financial struggles, highlighting a broader trend of challenges within the industry [12].